Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02292758 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02292758 is a Phase 2 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 36 participants.
The verdict
NCT02292758, a Phase 2 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally advanced/metastatic) and cannot be removed by surgery. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as cetuximab and bevacizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving irinotecan and cetuximab with or without bevacizumab may work betting in treating patients with colorectal cancer.
Interventions
- OTHER Placebo
- BIOLOGICAL Cetuximab
- OTHER Laboratory Biomarker Analysis
- DRUG Irinotecan
- BIOLOGICAL Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-12-12 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02292758
The ClinicalTrials.gov registry entry for NCT02292758 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02292758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02292758 about?
NCT02292758 is a clinical study titled "Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery". This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally advanced/metastatic) and cannot be removed by surgery. Irinotecan may stop the grow...
What is the current status of trial NCT02292758?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-12-12. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT02292758?
The interventions under investigation include: Placebo (OTHER), Cetuximab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Irinotecan (DRUG), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02292758?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.